Valuation: Alkermes plc

Market Cap 829.59Cr 719.09Cr 674.09Cr 614.64Cr 1.16TCr 79TCr 1.18TCr 7.94TCr 3.1TCr 40TCr 3.11TCr 3.05TCr 1,32200Cr P/E 2026 *
-96.9x
P/E 2027 * 68.1x
Enterprise Value 903.98Cr 783.57Cr 734.54Cr 669.76Cr 1.26TCr 86TCr 1.28TCr 8.65TCr 3.38TCr 43TCr 3.39TCr 3.32TCr 1,44100Cr EV / Sales 2026 *
4.95x
EV / Sales 2027 * 4.61x
Free-Float
89.44%
Yield 2026 *
-
Yield 2027 * -
1 day-1.65%
1 week+2.23%
Current month+0.94%
1 month-4.67%
3 months+27.09%
6 months+49.13%
Current year+76.73%
1 week 48.39
Extreme 48.39
51.66
1 month 47.66
Extreme 47.66
53.88
Current year 27
Extreme 27
55.67
1 year 25.16
Extreme 25.165
55.67
3 years 22.01
Extreme 22.01
55.67
5 years 21.24
Extreme 21.24
55.67
10 years 11.98
Extreme 11.98
71.22
Manager TitleAgeSince
Chief Executive Officer 53 01/08/2026
Director of Finance/CFO 53 15/09/2025
Chief Tech/Sci/R&D Officer 58 30/05/2017
Director TitleAgeSince
Chairman 64 01/09/2011
Director/Board Member 74 26/05/2016
Director/Board Member 63 30/03/2018
Date Insider Type Main position Quantity % Market Cap.
05/08/26 Free

Chief Executive Officer

2,17,534 0.1297%
03/08/26 Sell

Compliance Officer

-2,034 0.0012%
03/08/26 Fiscal year

Chief Technology Officer

19,000 0.0113%
Change 5-day change 1-year change 3-year change Capi.($)
-1.65%+2.23%+72.72%+76.42% 829.59Cr
+1.17%+1.09%+4.03%+15.74% 4.92TCr
-1.59%+2.12%+460.02%+573.56% 4.33TCr
-0.85%+7.95%+15.77%+80.09% 4.05TCr
-0.08%+3.91%+26.96%+9.86% 3.98TCr
0.00%+3.59%+20.51%+48.00% 3.27TCr
-3.61%-1.45% - - 1.62TCr
-2.52%-0.52%+24.35%+118.05% 1.62TCr
+0.72%+0.31%+4.94%+21.70% 1.4TCr
-1.09%+5.94%+81.46%+31.15% 1.34TCr
Average -0.95%+2.29%+78.97%+108.29% 2.74TCr
Weighted average by Cap. -0.61%+2.69%+95.78%+132.40%

Financials

2026 *2027 *
Net sales 182.49Cr 158.18Cr 148.28Cr 135.21Cr 254.41Cr 17TCr 258.48Cr 1.75TCr 681.64Cr 8.72TCr 685.13Cr 670.29Cr 29TCr 194.48Cr 168.58Cr 158.03Cr 144.09Cr 271.13Cr 19TCr 275.47Cr 1.86TCr 726.44Cr 9.29TCr 730.15Cr 714.34Cr 31TCr
Net income -8.99Cr -7.79Cr -7.31Cr -6.66Cr -13Cr -858.19Cr -13Cr -86Cr -34Cr -429.59Cr -34Cr -33Cr -1.43TCr 12Cr 10Cr 9.77Cr 8.91Cr 17Cr 1.15TCr 17Cr 115.09Cr 45Cr 574.67Cr 45Cr 44Cr 1.92TCr
Net Debt 74Cr 64Cr 60Cr 55Cr 103.71Cr 7.1TCr 105.37Cr 711.75Cr 277.87Cr 3.55TCr 279.29Cr 273.24Cr 12TCr 67Cr 58Cr 54Cr 50Cr 93Cr 6.39TCr 95Cr 640.96Cr 250.23Cr 3.2TCr 251.51Cr 246.06Cr 11TCr
Logo Alkermes plc
Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.
Employees
2,050
Date Price Change Volume
13/26/13 $49.45 -1.65% 15,46,632
12/26/12 $50.28 +2.17% 13,15,646
11/26/11 $49.21 -0.38% 13,73,601
10/26/10 $49.40 +0.47% 15,11,275
07/26/07 $49.17 +1.65% 11,10,968
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
49.45USD
Average target price
56.00USD
Spread / Average Target
+13.25%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALKS Stock